- Home
- AVK vs SIGA Comparison
AVK vs SIGA Comparison
Compare AVK & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVK
- SIGA
- Stock Information
- Founded
- AVK 2003
- SIGA 1995
- Country
- AVK United States
- SIGA United States
- Employees
- AVK N/A
- SIGA N/A
- Industry
- AVK Trusts Except Educational Religious and Charitable
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- AVK Finance
- SIGA Health Care
- Exchange
- AVK Nasdaq
- SIGA Nasdaq
- Market Cap
- AVK 561.1M
- SIGA 515.1M
- IPO Year
- AVK N/A
- SIGA 1997
- Fundamental
- Price
- AVK $12.62
- SIGA $8.30
- Analyst Decision
- AVK
- SIGA
- Analyst Count
- AVK 0
- SIGA 0
- Target Price
- AVK N/A
- SIGA N/A
- AVG Volume (30 Days)
- AVK 112.9K
- SIGA 416.9K
- Earning Date
- AVK 01-01-0001
- SIGA 11-06-2025
- Dividend Yield
- AVK 11.85%
- SIGA 7.22%
- EPS Growth
- AVK N/A
- SIGA N/A
- EPS
- AVK N/A
- SIGA 1.14
- Revenue
- AVK N/A
- SIGA $179,639,422.00
- Revenue This Year
- AVK N/A
- SIGA N/A
- Revenue Next Year
- AVK N/A
- SIGA $115.06
- P/E Ratio
- AVK N/A
- SIGA $7.29
- Revenue Growth
- AVK N/A
- SIGA 3.86
- 52 Week Low
- AVK $9.24
- SIGA $4.95
- 52 Week High
- AVK $12.16
- SIGA $9.62
- Technical
- Relative Strength Index (RSI)
- AVK 46.29
- SIGA 44.81
- Support Level
- AVK $12.75
- SIGA $8.00
- Resistance Level
- AVK $13.04
- SIGA $8.53
- Average True Range (ATR)
- AVK 0.15
- SIGA 0.31
- MACD
- AVK -0.02
- SIGA -0.07
- Stochastic Oscillator
- AVK 21.50
- SIGA 20.54
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.